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The cyanobacterial neurotoxin 𝛽-N-methylamino-L-alanine (BMAA) is considered to be an “excitotoxin,” and its suggested
mechanism of action is killing neurons. Long-term exposure to L-BMAA is believed to lead to neurodegenerative diseases including
Parkinson’s and Alzheimer’s diseases and amyotrophic lateral sclerosis (Lou Gehrig’s disease). Objectives of this study were to
determine the presumptive median lethal dose (LD
50
), the Lowest-Observed-Adverse-Effect Level (LOAEL), and histopathologic
lesions caused by the naturally occurring BMAA isomer, L-BMAA, in mice. Seventy NIH Swiss Outbred mice (35 male and 35
female) were used. Treatment group mice were injected intraperitoneally with 0.03, 0.3, 1, 2, and 3mg/g body weight L-BMAA,
respectively, and control mice were sham-injected. The presumptive LD
50
of L-BMAA was 3mg/g BW and the LOAEL was 2mg/g
BW.There were no histopathologic lesions in brain, liver, heart, kidney, lung, or spleen in any of the mice during the 14-day study.
L-BMAAwas detected in brains and livers in all of treatedmice but not in control mice.Males injected with 0.03mg/g BW, 0.3mg/g
BW, and 3.0mg/g BW L-BMAA showed consistently higher concentrations (P < 0.01) in brain and liver samples as compared to
females in those respective groups.
1. Introduction
𝛽-N-Methylamino-L-alanine (BMAA) is a nonprotein amino
acid. Its molecular formula is C
4
H
10
N
2
O
2
(Figure 1), its CAS
number is 15920-93-1, and it has a molar mass of 118.13 g/mol.
The naturally occurring isomer of BMAA is L-BMAA [1].
Exposure to L-BMAAmay cause neuronal death in the brains
of humans and animals, and exposure may play a role in
the pathogenesis of Parkinson’s and Alzheimer’s diseases and
amyotrophic lateral sclerosis or Lou Gehrig’s disease.
Various doses of L-BMAA have been administered
intraperitoneally (IP) to mice, rats, and chickens [1–3], orally
to monkeys and mice [4–6], and intracerebroventricularly
to mice and rats [7–11]. Several studies demonstrated that a
single dose of L-BMAA causes hyperexcitability, inability to
extend the legs, a dragging gait, myoclonus, and convulsions
[1, 2, 7].
Additional studies demonstrated similar findings, and
this is likely because L-BMAA crosses the blood-brain barrier
and causes irreversible damage [3, 8, 12, 13]. In rats, L-BMAA
adversely affects monoamine neurons in the substantia nigra,
and it decreases noradrenaline levels in the hypothalamus
[13].
Clinical symptoms caused by L-BMAAneurotoxicitymay
be due to changes in cholinergic and glutamatergic neuro-
transmission, primarily due to a decrease in the number of
glutamatergic receptors [9–11]. Glutamate acts on the ligand-
gated receptor channels N-methyl-D-aspartic acid (NMDA),
2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propionic acid
(AMPA), and kainate receptors at the postsynaptic mem-
brane. This is an important mechanism in memory function
and for the sensing of environmental cues [14–18]. Because L-
BMAA has glutamate receptor agonist activity in mammals
and plants [19, 20], Couratier et al. [21] suggested that neu-
ronal degeneration in ALS is initiated at the level of glutamate
AMPA/kainate receptors.The initiation of neurotoxicity may
be due to direct action on NMDA receptors and activation
of metabotropic glutamate receptors 5 (mGluR5) and/or by
inducing oxidative stress [22–26].
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Figure 1: L-BMAA chemical structure.
Additional studies demonstrated that L-BMAA inhibits
the cysteine/glutamate antiporter (system Xc-) that mediates
cysteine uptake and increases oxidative stress [26], and/or it
may activate AMPA/kainate receptors which causes selective
death of motor neurons [24]. L-BMAA concentrations as low
as 30 𝜇M cause motor neuron death [24], a concentration of
10 𝜇M enhances neuronal death [25, 26], and a concentration
of 3mM causes death of entire cortical neuron populations
[27]. L-BMAA is actively transferred across the blood-brain
barrier [28] where it also increases output of dopamine by
affected neurons [29].
Fruit bats, a known source of L-BMAA, are used to make
a traditional soup by the Chamorro people in Guam [30,
31]. Cox and Sacks [32] calculated that a human weighing
70 kg body weight (BW) and eating two fruit bats of 500 g
each will ingest approximately 28mg L-BMAA/kg BW [32].
Perry et al. [5], however, did not observe any behavioral,
neurochemical, or neuropathological changes in mice orally
dosed with 0.5mg of L-BMAA/g BW/day for 11 weeks, and
lesions were not seen histopathologically in the brain. Cruz-
Aguado et al. [6] also did not observe neuronal damage after
orally dosing mice with 1mg LBMAA (28mg/kg daily) for 30
days.
Spencer et al. [4] were the first to demonstrate that
administering 100–315mg L-BMAA/kg daily for up to 12
weeks to monkeys caused clinical symptoms very similar to
amyotrophic lateral sclerosis/Parkinson dementia complex
(ALS/PDC), and, in another study [4], they suggested a
significant role for L-BMAA in the etiology of ALS-PDC
[4]. However, Dawson Jr. et al. [33] reported sex-dependent
changes in motor function and spinal cord neurochemistry,
and they concluded that these changes were not related to
ALS/PDC. More recently, L-BMAA has been detected in
many fish species and aquatic plants, as well as open water
samples from reservoirs in Nebraska, USA, which suggests
that a direct human exposure to L-BMAAmay occur through
the food chain [33, 34].
Although earlier studies have investigated the acute
neurotoxic effects of L-BMAA in several animal species
[35], Buenz and Howe [36] demonstrated that direct admin-
istration of BMAA to the mouse’s brain causes sporadic
death of hippocampal neurons, and they demonstrated this
histopathologically using TUNEL staining after subcuta-
neous injection of 600mg/kg of L-BMAA in rat pups.
The objectives of the present study were to determine
the presumptive LD
50
and LOAEL for L-BMAA in mice.
Table 1: L-BMAA doses and study design. BW: body weight.
Group L-BMAA dose (mg/g BW) Number of mice
Male Female
A 0.03 7 7
B 0.3 7 7
C 1 6 6
D 2 6 6
E 3 6 6
Control 0 3 3
In addition, brain and other selected tissue specimens were
examined for histopathologic lesions.
2. Materials and Methods
2.1. L-BMAA and Doses. Five doses of L-BMAA (supplied
by the Institute for Ethnomedicine, Jackson Hole, WY, USA)
were prepared in sterile water and adjusted to pH 6.5 with
NaOH [1] prior to IP injection.
Each dose was dissolved in 0.5mL of sterile H
2
O and
calculated as follows depending on each mouse weight:
Dose (mg/g BW) × mouse weight (15–20 g) = 𝑌
mg/mouse (L-BMAA/mouse), for example, Group E
Dose (3mg/g BW) × 18 g = 54mg/0.5mL.
2.2. Animals and Housing. Thirty-five male and 35 female
NIH Swiss Outbred mice (Harlan Laboratories, Indianapolis,
IN, USA) weighing 15–20 g each were used. Males and
females were housed separately, and they were fed a standard
mouse diet and water ad libitum. The mice were allowed
to acclimate for 3 days prior to IP injection, and they were
housed and treated according to University of Nebraska-
Lincoln Institutional Animal Care andUseCommittee guide-
lines.
2.3. Study Design. Duration of the study was 14 days. Mice
were randomly assigned to six groups, and equal numbers
of males and females were included in each group (Table 1).
Each mouse was injected with 0.5mL of the respective L-
BMAA preparation depending on individual body weight
and observed 4 times daily for 14 days; control mice received
sterile water only.
2.4. Presumptive Median Lethal Dose (LD
50
) and the Lowest-
Observed-Adverse-Effect Level (LOAEL). Presumptive LD
50
was defined as the L-BMAA dose that caused one-half of
the mice receiving that dose to display clinical symptoms
requiring humane euthanasia. The LOAEL was defined as
the lowest dose of L-BMAA that caused adverse clinical
symptoms after IP injection [37].
2.5. Tissue Samples and Histopathology. Mice displaying
adverse clinical symptoms were humanely euthanized, and
all remaining mice were euthanized 14 days after injection.
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Table 2: Number of brain and liver specimens collected from each
mice group.
Group L-BMAA dose mg/g BW Female Male
Control 0 1 1
A 0.03 3 3
B 0.3 3 3
E 3 3 3
Specimens of brain, liver, lung, heart, spleen, and kidney from
one male and one female in each group were immediately
immersed in 10% phosphate-buffered formalin. After 24
hours of fixation, brains were transversely sectioned at five
levels in a cranial to caudal fashion, and then all specimens
were routinely processed for histopathology. Sections of each
specimen were cut at 4-5 𝜇m and stained with hematoxylin
and eosin. Brain and liver specimens from all remainingmice
were frozen for L-BMAA extraction [3].
2.6. L-BMAA Extraction. Frozen liver and brain specimens
from 20 mice representing Control, A, B, and E group
(Table 2)were thawed, and 50mgof the frontal brain lobe and
50mg of the liver from each mouse were weighed separately
in 2mL glass amber tubes.
Five hundred 𝜇L of 6M HCl was added, and the mixture
was sonicated for 30 seconds and then vortexed. After heating
for 16 hours at 110∘C, 100 𝜇L of the mixture was transferred
to a Millipore Ultrafilter centrifuge tube (EMD Millipore
Corporation, Billerica, MA, USA) and centrifuged for 3min
at 1300 rpm. The filtered solution was then evaporated to
dryness by using N
2
gas and heating at 45∘C [34].
2.7. L-BMAA Detection Methods. Brain and liver samples
from the 20 male and female mice (Table 2) were dried using
established protocol and analyzed using Ultra Performance
Liquid Chromatography (UPLC), and Liquid Chromatogra-
phy/Mass Spectrometry/Mass Spectrometry (LC/MS/MS) at
the Institute for Ethnomedicine (IEM), Jackson Hole, WY,
USA [38, 39].
2.7.1. Ultra Performance Liquid Chromatography Method
(UPLC-UV). L-BMAA was detected in mouse tissues using
Waters Acquity pressure UPLC-UV and in-line single
quadrupole mass spectrometry (UPLC-MS) following a val-
idated method [39]. Hydrolyzed samples were derivatized
with AQC. Eluents were purchased from Waters (Eluent A:
part #186003838, Eluent B: part #186003839); composition
is proprietary. Separation was achieved by reverse phase
chromatography over 9.5 minutes on a Waters AccQ-Tag
Ultra column (part #186003837, 2.1 × 100mm) at temperature
of 55∘C and flow rate of 0.7mL/min. The elution gradients
were 0.0min = 0.1% B; 0.54min = 0.1% B curve 6; 6.24min
= 9.1% B curve 7; 7.74min = 21.2% B curve 6; 8.04min =
59.6% B curve 6; 8.73min= 0.1% B curve 6; 9.5min = 0.1%
B curve 6. L-BMAA was identified using mass and retention
time in comparison with an authenticated L-BMAA standard
[38, 40–42].
2.7.2. Liquid Chromatography-Tandem Mass Spectrometry
Method (LC/MS/MS). Hydrolyzed samples were deriva-
tized with 6-aminoquinolyl-N-hydroxysuccinimidyl carba-
mate (AQC). L-BMAA analyses were performed using a
triple quadrupole instrument (Thermo Scientific Finnegan
TSQ Quantum UltraAM, San Jose, CA) and separation was
performed by using Waters Acquity-UPLC system with a
Binary Solvent Manager, Sample Manager, and a Waters
AccQ-Tag Ultra column (part #186003837, 2.1 × 100mm)
at 55∘C. Separation was completed using 0.65mL/min in
aqueous 0.1% (v/v) formic acid (Eluent A) and 0.1% (v/v)
formic acid in acetonitrile (Eluent B) with the following
elution gradient: 0.0min = 99.1% A; 0.5min = 99.1% A curve
6; 2min = 95% A curve 6; 3min = 95% A curve 6; 5.5min =
90%A curve 8; 6min = 15%A curve 6; 6.5min = 15%A curve
6; 6.6min = 99.1% A curve 6; 8min = 99.1% A curve 6. The
heated electrospray ionization (H-ESI) probe was supplied
with nitrogen gas at a nebulizing pressure of 40 psi and a
vaporizer temperature of 400∘C.
The mass spectrometer operating conditions were as
follows: capillary offset of 35, capillary temperature of 270∘C,
auxiliary gas pressure of 35, spray voltage 3500V, source
collision energy of 0 eV, multiplier voltage of −1719V, and
tube lens offset of 110.The second quadrupolewas pressurized
to 1.0m Torr with argon. In the first quadrupole filter, ion
m/z 459 was isolated as the precursor ion and subjected to
collision induced dissociation (CID). The second step mass
filtering was completed using selective reaction monitoring
(SRM) of L-BMAA after CID in the collision cell.
The m/z transitions monitored were 459–119 CE 21 eV;
459–289 CE 17 eV; 459–171 CE 38 eV. The three product
ion resultants originating from derivatized L-BMAA (119,
289, and 171 m/z) were scanned and detected by the third
quadrupole and their relative abundances quantified. The
ratio of the three product ions was compared to the product
ion ratios of an authenticated L-BMAA standard [38–41].
2.8. Statistical Analysis. Results were presented as mean ±
standard deviation (SD) using three results’ reading. The
statistical analysis was used in our study to show the degree
of significance of our data.
3. Results
3.1. Presumptive Median Lethal Dose (LD
50
). The presump-
tive LD
50
, the dose at which 50% of the mice became
moribund and required euthanasia, was 3mg/g L-BMAA
BW. Four males and three females in the group given this
dose developed myoclonus, convulsions, and uncontrolled
urination and defecation within 20 minutes of injection.
3.2. Lowest-Observed-Adverse-Effect Level (LOAEL). The
lowest administered dose that caused the previously
described clinical symptoms was 2mg/g L-BMAA BW;
one female mouse in the group given this dose required
euthanasia 45 minutes after injection.
4 Journal of Toxicology
Table 3: L-BMAA concentrations (𝜇g/g) in brains and livers of mice as detected by UPLC-UV. Each value is the mean of three replicates ±
standard deviation. BW: body weight; F: female; M: male. A, B, and E: mice treated (0.03, 0.3, and 3mg/g BW) groups.
L-BMAA dose (mg/g BW) Gender L-BMAA (𝜇g/g) in brain L-BMAA (𝜇g/g) in liver
Control (0) F 0.00 ± 0.00 0.00 ± 0.00
M 0.00 ± 0.00 0.00 ± 0.00
(A) 0.03 F 0.06 ± 0.03 0.05 ± 0.01
M 0.28 ± 0.05 0.10 ± 0.01
(B) 0.30 F 0.16 ± 0.02 0.14 ± 0.05
M 1.83 ± 0.69 1.15 ± 0.04
(E) 3.00 F 2.45 ± 0.33 1.80 ± 0.09
M 4.49 ± 0.21 2.35 ± 0.30
Table 4: L-BMAA concentrations (𝜇g/g) in brains and livers of mice as detected by LC/MS/MS chromatography. Each value is the mean of
three replicates ± standard deviation. BW: body weight; F: female; M: male. A, B, and E: mice treated (0.03, 0.3, and 3mg/g BW) groups.
L-BMAA dose (mg/g BW) Gender L-BMAA (𝜇g/g) in brain L-BMAA (𝜇g/g) in liver
Control (0) F 0.00 ± 0.00 0.00 ± 0.00
M 0.00 ± 0.00 0.00 ± 0.00
(A) 0.03 F 1.61 ± 0.41 1.12 ± 0.10
M 3.34 ± 0.52 1.53 ± 0.21
(B) 0.30 F 4.69 ± 0.34 2.64 ± 0.28
M 8.41 ± 0.56 3.85 ± 0.22
(E) 3.00 F 21.79 ± 0.92 11.94 ± 0.64
M 32.62 ± 0.99 15.59 ± 0.57
3.3. Gross Examination and Histopathology. There were no
gross lesions at necropsy in any of the mice. There were no
histopathologic lesions in the brain, liver, lung, kidney, heart,
or spleen from any of the mice, including one male and one
female in the 3mg L-BMAA/g BW group and the one female
in the 2mg L-BMAA/g BW group that had displayed adverse
clinical symptoms.
3.4. L-BMAA in Brain and Liver Specimens
3.4.1. Ultra Performance Liquid Chromatography Results.
Table 3 shows L-BMAA concentrations in brains and livers
as detected by UPLC-UV, with the concentrations of L-
BMAA in male subgroups being higher than that in female
subgroups. Figure 2 will show UPLC-UV chromatographic
detection figure of L-BMAA in male mouse brain injected
with 3mg/g BW. Figures 3 and 4 will show UPLC-UV results
comparison of L-BMAA concentrations in (𝜇g/g) in brains
and liver of male and female mice.
3.4.2. Liquid Chromatography-Tandem Mass Spectrometry
Results. To confirm the results of L-BMAA concentrations
detected in extracted brain and liver samples from treated and
control mice using UPLC-UV, LC/MS/MS chromatography
was performed on these same samples. Results are given
in Table 4. Figure 5 will show LC/MS/MS chromatographic
detection figure of L-BMAA in male mouse brain injected
with 3mg/g BW. Comparison of L-BMAA concentrations
in male and female brains and livers using LC/MS/MS
chromatography is shown in Figures 6 and 7, respectively.
4. Discussion
Results of this study indicate that the presumptive LD
50
of L-
BMAA is 3mg/g BW and the LOAEL of L-BMAA is 2mg/g
BW in male and female NIH Swiss Outbred mice when
administered intraperitoneally. Clinical symptoms such as
myoclonus, convulsions, and uncontrollable urination and
defecation seen in some of the mice are symptoms similar
to those reported by other investigators [2, 7, 8] regardless
of animal species used or routes of L-BMAA administration
[43]. Other symptoms included a dragging gait, weakness,
and convulsions [2]; hyperexcitability and shaking [7]; ataxia,
rolling, unsteady gait, andmyoclonia [8]. Studies that did not
report any clinical symptoms or neuropathological changes
presumably used insufficient doses of BMAA or routes of
administration, that is, mainly by mouth [5, 6, 43]. Tissue
sections were cut at 4-5 𝜇m and stained with hematoxylin
and eosin. Only the front lope of brain and a part of
the liver were used to measure the accumulated BMAA
from our original doses [44]. This lack of histopathologic
lesions in the brain may not be uncommon. However, Pablo
et al. [44] failed to detect lesions in brain samples taken
from ALS and AD deceased patients. Also, Perry et al. [5]
could not detect any neurochemical and neuropathological
changes in BMAA orally exposed mice [6]. In addition,
no histopathologic changes were seen in the hippocampus
of neonatal rats injected subcutaneously with 0.2mg/g BW
BMAA [45]. Exposure to BMAA is believed to kill neurons in
the brain, leading to neurodegenerative diseases. In one study,
neuronal death occurred within 24 hours after 0.6mg/g BW
BMAA was injected subcutaneously in neonatal rats.
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Figure 2: UPLC chromatography of L-BMAA level (4.66 𝜇g/g) in brain of male mouse with dose 3mg/g BW.
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Figure 3: Comparison of L-BMAA concentrations (𝜇g/g) in brains
of male and female mice as detected by UPLC-UV. T-bars represent
the mean of 𝑛 (𝑛 = 3) ± SD. A, B, and E: mice treated (0.03, 0.3, and
3mg/g BW) groups.
The results showed a significantly higher concentration of
L-BMAA, again demonstrating that the LC/MS/MSwasmore
sensitive than the UPLC-UV method. Other investigators
have reported that IP administration of L-BMAA causes
selective degeneration of cerebellar cortical neurons in rat
pups [3] and intracerebral administration of L-BMAA causes
sporadic death of hippocampal neurons in mice [36].
Histopathologic lesionswere not seen in brains or in other
selected tissues from treated mice, including symptomatic
mice, in the present study.This lack of histopathologic lesions
might suggest that L-BMAA causes a “biochemical lesion” as
opposed to a histopathologic lesion in brain and other tissues
under the conditions of this study. To truly focus on possible
histopathologic changes caused by L-BMAA in tissues from
mice, however, future studies might examine larger num-
bers of mice and employ perfusion fixation and advanced
staining techniques. Buenz and Howe [36] demonstrated
that direct administration of L-BMAA to the mouse’s brain
causes sporadic death of hippocampal neurons, and they
demonstrated this histopathologically using TUNEL staining
6 Journal of Toxicology
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Figure 4: Comparison of L-BMAA concentrations (𝜇g/g) in livers of male and female mice as detected by UPLC-UV. T-bars represent the
mean of 𝑛 (𝑛 = 3) ± SD. A, B, and E: mice treated (0.03, 0.3, and 3mg/g BW) groups.
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Figure 5: LC/MS/MS chromatography of L-BMAA level (33.6 𝜇g/g) in male mouse brain tissue with a dose of 3mg/g BW.
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Figure 6: Comparison of L-BMAA concentrations (𝜇g/g) in brains
ofmale and femalemice as detected by LC/MS/MS chromatography.
T-bars represent the mean of 𝑛 (𝑛 = 3) ± SD. A, B, and E: mice
treated (0.03, 0.3, and 3mg/g BW) groups.
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Figure 7: Comparison of L-BMAAconcentrations (𝜇g/g) in livers of
male and femalemice as detected byLC/MS/MS chromatography. T-
bars represent the mean of 𝑛 (𝑛 = 3) ± SD. A, B, and E: mice treated
(0.03, 0.3, and 3mg/g BW) groups.
after subcutaneous injection of 600mg/kg of L-BMAA in
rat pups [45]. The method of administrating L-BMAA was
intraperitoneal injection which was found to be accurate to
induce acute neurotoxicity in mice brain as was shown in a
study in 1990 [3].
LC/MS/MS chromatographywas shown to bemore sensi-
tive (𝑃 < 0.01) than UPLC-UV when determining L-BMAA
concentrations in tissues. The use of both methods consis-
tently detected higher concentrations of L-BMAA in brain
and liver samples frommales in Groups A (0.03mg/g BW), B
(0.3mg/g BW), and E (3.0mg/g BW) as compared to females
in those groups (𝑃 < 0.01) which could be result of lower
metabolic rate in female than in male [46, 47].
5. Conclusions
In conclusion, the presumptive LD
50
of L-BMAA is 3mg/gm
BW and the LOAEL of L-BMAA is 2mg/g BW in male
and female NIH Swiss Outbred mice when administered
intraperitoneally, and this animal model may prove useful
for investigating the role of L-BMAA in neurodegenerative
diseases. LC/MS/MS chromatography is more sensitive (𝑃 <
0.01) than UPLC-UV when determining L-BMAA concen-
trations in mouse tissues.
Future studies should further examine whether L-BMAA
concentrations in brain, liver, and perhaps other tissues are
influenced by gender. Studies might be designed to examine
the long-term, chronic effects of administering L-BMAA
at doses lower than the LOAEL for longer than 14 days.
Perhaps then a relationship between L-BMAA exposure and
neurodegenerative diseases in humans can be determined.
L-BMAA has been shown clearly to be a neurotoxin in our
mousemodel and in other laboratory animals.This reinforces
the notion that L-BMAA can cause serious neurodegen-
erative diseases in humans (and animals) as it can pass
easily through the blood-brain barrier [12], and it can also
transfer from mother to offspring through their milk [48].
When administered intraperitoneally tomice at doses greater
than 2mg/g BW, the onset of adverse clinical symptoms is
rapid. A long-term study of the relation between human
neurodegenerative diseases such as ALS and the presence
of BMAA in the same geographic environment can help
us to determine the effect of the cyanobacterial neurotoxin
(BMAA) on human inUSA andworldwide, similar to the one
recently done by Delzor and his colleagues in France [49].
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